CXCR4 and acute myeloid leukemia: Furthermore, ulocuplumab is a human IgG4 monoclonal anti-CXCR4 antibody that has therapeutic potential for several hematologic malignancies including AML [122], clinical studies have demonstrated the ability of ulocuplumab to mobilise leukemic cells into the circulation, rendering them more susceptible to chemotherapy-induced toxicity in patients with AML [123, 124].